DOI QR코드

DOI QR Code

COX-2 Expression in Renal Cell Carcinoma and Correlations with Tumor Grade, Stage and Patient Prognosis

  • Tabriz, Hedieh Moradi (Pathology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Mirzaalizadeh, Marzieh (Pathology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Gooran, Shahram (Urology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Niki, Farzaneh (Medical Technology, Sina Hospital, Tehran University of Medical Sciences) ;
  • Jabri, Maryam (Pathology, Sina Hospital, Tehran University of Medical Sciences)
  • Published : 2016.03.07

Abstract

Background: Cyclooxygenase 2 (COX-2) is important as an enzyme in the pathway leading to the production of prostaglandin E2 (PGE2) and arachidonic acid. This pathway is known to play a role in inflammation, tumor growth, invasiveness and metastasis, inhibition of apoptosis and angiogenesis. Inhibition of COX-2 has been shown to be a promising antitumor and antiangiogenic strategy in several tumor types, including renal cell carcinoma (RCC). Therefore, we decided to evaluate the immunohistochemical expression of this marker and its association with several clinicopathological characteristics in a series of cases. Materials and Methods: COX-2 expression was examined immunohistochemically in tumor tissues obtained from 96 patients who underwent radical (94 cases) or partial (2 cases) nephrectomy. Correlations between COX-2 expression and clinicopathologic findings including pathologic stage, nuclear grade and other indicator of prognosis were examined. Results: Of 96 tumors, 20.9% were positive for COX-2 expression. A correlation was found between COX-2 expression and tumor histological subtype (P=0.03).The papillary subtype showed maximum expression of this marker (43.8%) and the clear subtype minimum (14.7%). There were also possible links between COX-2 expression and pathologic stage, nuclear grade and nodal involvement but the results were not statistically significant (P=0.8, P= 0.14 and P=0.06, respectively). No correlation was found between COX2 expression and patient age, gender, tumor size, metastasis or survival. Conclusions: In our study, COX-2 expression was correlated with the histological subtype of RCC. Additional research is required to determine the link between COX-2 expression and prognosis and also evaluation of probable effectiveness of COX-2 inhibitor drugs in treatment of RCC patients.

Keywords

Renal cell carcinoma;COX-2 expression;IHC;prognosis

References

  1. Carter D, Greenson JK, Reuter VE, et al (2010). Sternberg's Diagnostic Surgical Pathology, Eds Mills SE. Lippincott Williams Wilkins, Philadelphia, 1757.
  2. Cho DS, Joo HJ , Oh DK, et al (2005). Cyclooxygenase-2 and P53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J, 46, 133-140. https://doi.org/10.3349/ymj.2005.46.1.133
  3. Dirim A, Haberal AN, Goren MR, et al (2008). VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int Urol Nephrol, 40, 861-868. https://doi.org/10.1007/s11255-008-9362-7
  4. Dubois RN, Abramson SB, Crofford L, et al (1998). Cyclooxygenase in biology and disease. FASEB J, 12, 1063-73. https://doi.org/10.1096/fasebj.12.12.1063
  5. Hasan G, Elife S, Aysenur AI, et al (2009). COX-2 expression and microvessel density in clear cell type renal cell carcinoma. Turk Pathologi Dergisi, 25, 13-19.
  6. Hashimoto Y, Kondo Y, Kimura G, et al (2004). Cyclooxygenase-2 expression and relationship to tumour progression in human renal cell carcinoma. Histopathol, 44, 353-359 https://doi.org/10.1111/j.1365-2559.2004.01853.x
  7. Kankuri-Tammilehto MK, Soderstrom KO, Pelliniemi TT, et al (2010). Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res, 30, 3023-3030.
  8. Kumar V, Abbas AK, Fausto N, Aster J (2010). Robbins and Cotran Pathologic Basis of Disease. Elsevier, Philadelphia, 964-6.
  9. Lee JW, Park JH, Suh JH, et al (2012). Cyclooxygenase-2 expression and its prognostic significance in clear cell renal cell carcinoma. Korean J Pathol, 46, 237-45. https://doi.org/10.4132/KoreanJPathol.2012.46.3.237
  10. Miyata Y, koga S, Kanda S, et al (2003). Expression of cyclooxygenase-2 in renal cell carcinoma: correlation with tumor cell proliferation, apoptosis, angiogenesis, expression of matrix metalloproteinase-2, and survival. Clin Cancer Res, 9, 1741-1749
  11. Mungan Mu, Gurel D, Canda AE, et al (2006).Expression of COX-2 in normal and pyelonephritic kidney, renal intraepithelial neoplasia and renal cell carcinoma. Eur Urol, 50, 92-7. https://doi.org/10.1016/j.eururo.2005.12.039
  12. Rosai J (2011). Rosai and Ackerman Surgical Pathology. Elsevier, Philadelphia, 1183-93.
  13. Schwandt A, Garcia J.A, Elson P, et al (2011). Clinical and immunomodulatory effects of celecoxib plus interferonalpha in metastatic renal cell carcinoma patient with COX-2 tumor immunostaining. J Clin Immunol, 31, 690-8 https://doi.org/10.1007/s10875-011-9530-x
  14. Sozen S, Gurocak S, Erdem O, et al (2008). Cyclooxygenase-2 expression: Does it have a probable role in tumorigenesis mechanisms of renal cell carcinoma. Int Urol Nephrol, 40, 295-301. https://doi.org/10.1007/s11255-007-9268-9
  15. Sun H, Wang H , Qin WJ, et al (2009). Expression of IGF-IR and COX-2 in renal cell carcinoma and their relationship with cell proliferation. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, 25, 384-50.
  16. Tawfik OW, Kramer B, Shideler B, et al (2007). Prognostic Significance of CD44, Platelet-Derived Growth Factor Receptor ${\alpha}$, and Cyclooxygenase 2 Expression in Renal Cell Carcinoma. Arch Pathol Lab Med, 131, 261-7.
  17. Tian SJ, Cheng L, Xu ZH, et al (2011). Relationship of renal cell carcinoma angiogenesis with heparanase and cyclooxygenase-2. J Shadong Univ, 49, 135-9.
  18. Tuna B, Yorukoglu K, Gurel D, Mungan U, Kirkali Z (2004). Significance of COX-2 expression in human renal cell carcinoma. Urol, 64, 1116-20. https://doi.org/10.1016/j.urology.2004.07.023
  19. Wang X, Zhang L, O'Neill A, et al (2013). Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts. Br J Cancer, 108, 319-26. https://doi.org/10.1038/bjc.2012.591
  20. Yoshimura R, Matsuyama M, Kawahito Y, et al (2004). Study of cyclooxygenase-2 in renal cell carcinoma. Int J Mol Med, 13, 229-33.

Cited by

  1. miR-433 protects pancreatic β cell growth in high-glucose conditions vol.16, pp.3, 2017, https://doi.org/10.3892/mmr.2017.6925